The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 92.50
Bid: 89.00
Ask: 96.00
Change: 0.00 (0.00%)
Spread: 7.00 (7.865%)
Open: 92.50
High: 92.50
Low: 92.50
Prev. Close: 92.50
UAV Live PriceLast checked at -
Unicorn AIM VCT is an Investment Trust

To provide shareholders with an attractive return from a diversified portfolio, predominantly invested in the shares of AIM quoted companies by maintaining dividend distributions to shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Voluntary Interim Management Statement

31 Jul 2018 11:54

RNS Number : 3266W
Unicorn AIM VCT PLC
31 July 2018
 

Unicorn AIM VCT PLC (UAV) - Voluntary Interim Management Statement

Unicorn AIM VCT plc ("the Company")

LEI: 21380057QDV7D34E9870

Interim Management Statement 

For the period from 1 April 2018 to 30 June 2018

Introduction

This voluntary Interim Management Statement (IMS) covers the three month period ended 30 June 2018, together with relevant information up to the date of publication. 

Investment Objective

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

It is also the objective that the Company should continue to qualify as a Venture Capital Trust, so that Shareholders benefit from the taxation advantages that this brings. To achieve this at least 70% of the Company's total assets are to be invested in qualifying investments of which 30% by VCT value (70% for funds raised after 6 April 2011) must be in ordinary shares carrying no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

Performance

Following a difficult first quarter of 2018, UK equity markets recovered strongly during the three month period to the end of June.

The FTSE All Share Index recorded a total return of +9.2% during the second quarter of 2018, while the FTSE AIM All Share Index ended the quarter up by +7.2%, on the same total return basis.

The performance of UK equity indices was surprisingly resilient during the quarter under review, despite an increasingly weak and unstable political backdrop. The negotiations with Brussels regarding Britain's exit from the European Union rumble on, while members of the UK's governing Conservative Party appear content to continue fighting amongst themselves. This lack of unity inevitably means it will be more difficult for the government to act decisively to resolve key issues such as immigration and trade between the UK and the remaining EU Member States. As a consequence, it is now generally accepted that the outlook for continued UK economic growth has become less positive, which may well impact on the performance of the UK equity market in due course. In the meantime, after a sustained rally during 2017, the value of Sterling has again started to weaken when compared to the US Dollar, which should have a beneficial effect on those British businesses that export the majority of their goods and services. This currency tailwind is almost certainly helping to support the valuation of the UK equity market and this is most evident in the FTSE 100 Index, which is mainly composed of large UK businesses that are typically global in scope.

The Company's performance was also positive during the period under review, with Net Asset Value per share increasing by 5.9%. Having started the period at 156.4 pence per share, the unaudited NAV per share as at 30 June 2018 was 165.7 pence per share.

VCT Qualifying Investments

Forty of the VCT qualifying investments held in the portfolio recorded share price gains during the period under review. Of these, nineteen investments generated capital gains in excess of £200,000 each.

Of particular note, were the four largest contributors to performance, which between them generated a combined total of almost £5.5 million in unrealised capital gains during the period.

These were:-

Abcam (+7.7%), a global leader in the supply of life science research tools, is the largest individual holding in the portfolio, representing 10% of total assets at the period end. Abcam continues to trade strongly in multiple international markets and has recently also been benefitting from favourable exchange rates. In a recent trading update, Abcam confirmed that revenues for the financial year ended 30 June 2018 had grown by over 10% and that EBITDA margins were in line with expectations. Abcam will release its full year results in September.

City Pub Group (+32.8%) owns and operates an estate of premium pubs across the southern half of England and Wales. The Group's pub estate comprises over 40 free houses located largely in London, cathedral cities and market towns, each of which is focused on appealing specifically to its local market. In May, City Pub Group released a trading update which confirmed that the business had traded strongly during the first eighteen weeks of its current financial year.

Tracsis (+14.1%), a leading provider of software and technology led products and services for the traffic data and transportation industry, released interim results shortly before the period under review commenced. Revenues and profits grew strongly in the first half of Tracsis' financial year and the business remains well positioned to deliver further growth during its second half.

VR Education (+62.8%) is a leading virtual reality technology company focused on the education space. The business floated on AIM in February 2018 and its shares have performed strongly since then, despite an absence of tangible newsflow.

Eight VCT qualifying holdings delivered negative contributions of more than £200,000 each, of which only two cost the VCT more than 0.5% in performance terms.

The two most meaningful detractors from performance were:-

Animalcare (-40.7%), is a pan-European animal health business. During the period, Animalcare released its first financial results since the transformational acquisition of Ecuphar, a Belgian competitor. Although the new management team are confident that the enlarged business will deliver double digit revenue and profit growth during its current financial year, investors remain nervous about the financial implications of a 'bad' Brexit and Animalcare's share price has been under pressure as a result.

ULS Technology (-17.4%), a provider of online technology platforms for the UK conveyancing market, released its full year financial results toward the end of the period under review. During the 12 month period ended 31 March 2018, ULS once again increased its share of the UK conveyancing market and delivered strong growth in revenues, underlying profits and an increased dividend. Current trading is challenging however, given reduced instruction levels in the residential housing market. Despite this current issue, the Board of ULS remains positive about the outlook for the business.

Non-Qualifying Investments

The performance of the non-qualifying investments was stable during the period under review. With the exception of Royal Dutch Shell, there were no significant share price movements to report on. The investment in Shell was short term in nature and was made in order to maintain liquidity and in preference to holding excessive levels of cash following the successful Offer for Subscription which closed in November 2017. Shell's share price performed strongly during the period and the VCT's holding was sold in its entirety in June 2018, crystallising a total return on investment of £529k.

 

Other Material Transactions

One new VCT qualifying investment was made during the period with £1.5 million being allocated to Microsaic Systems, a developer of mass spectrometry instruments that are designed to improve the efficiency of pharmaceutical research and manufacturing.

Additional VCT qualifying shares, to the value of £0.5 million, were acquired in Access Intelligence, as part of a placing of new shares. 

Shares were acquired in Lloyds Banking Group and Legal & General, which are both non-qualifying, short term investments and are being held for liquidity purposes.

Top Ten Holdings at 30 June 2018

Stock

% of fund

 

 

Abcam

10.0

Tracsis

4.8

Anpario

4.7

Mattioli Woods 

3.9

City Pub Group

3.7

Maxcyte

3.4

Tristel

2.6

ULS Technology

2.5

Victrex

2.5

Keywords Studios

2.2

Total

40.3

Share Buy-Backs

During the period from 1 April 2018 to 30 June 2018, the Company bought back 741,000 of its own Ordinary Shares for cancellation, at an average price, including costs of 141.7 pence per share. The average discount to underlying Net Asset Value at which these shares were purchased was 12.3%.

There were 117,833,174 Ordinary Shares in issue as at 30 June 2018.

Dividends

As previously advised, the Board has declared an interim dividend of 3.0 pence per share in respect of the Company's half-year ended 31 March 2018. This interim dividend will be paid on 10 August 2018 to Shareholders on the register at the close of business on 20 July 2018.

 

Material Events

There were no material events during the period from 1 April 2018 to 30 June 2018.

Chris Hutchinson

Unicorn Asset Management

Investment Manager

31 July 2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKMGFNGMMGRZM
Date   Source Headline
21st Feb 202311:43 amRNSNet Asset Value(s)
14th Feb 202312:42 pmRNSIssue of Equity
13th Feb 20234:53 pmRNSTransaction in Own Shares
7th Feb 20236:14 pmRNSResult of AGM
6th Feb 20235:30 pmRNSOffer for Subscription Update
6th Feb 202312:02 pmRNSOffer for Subscription – Update
6th Feb 20237:00 amRNSNet Asset Value(s)
1st Feb 202310:34 amRNSTotal Voting Rights
30th Jan 202311:24 amRNSInterim Management Statement
24th Jan 202312:09 pmRNSOffer for Subscription and Issue of Prospectus
16th Jan 20239:51 amRNSTransaction in Own Shares
6th Jan 20233:06 pmRNSNet Asset Value(s)
14th Dec 20227:00 amRNSFinal Results
8th Dec 202210:12 amRNSIntention to Launch an Offer
5th Dec 20222:43 pmRNSNet Asset Value(s)
4th Nov 20225:47 pmRNSNet Asset Value(s)
21st Oct 20221:38 pmRNSNet Asset Value(s)
3rd Oct 202212:45 pmRNSTotal Voting Rights
20th Sep 20226:19 pmRNSTransaction in Own Shares
5th Sep 202212:32 pmRNSNet Asset Value(s)
11th Aug 202211:27 amRNSIssue of Equity
4th Aug 20222:47 pmRNSNet Asset Value(s)
26th Jul 202211:30 amRNSInterim Management Statement
7th Jul 20229:50 amRNSNet Asset Value(s)
1st Jul 202210:00 amRNSTotal Voting Rights
22nd Jun 20225:44 pmRNSTransaction in Own Shares
14th Jun 20223:27 pmRNSNet Asset Value(s)
10th Jun 20227:00 amRNSHalf-year Report
24th May 20222:26 pmRNSDirectorate Change
6th May 202212:33 pmRNSNet Asset Value(s)
11th Apr 20229:02 amRNSNet Asset Value(s) Replacement
7th Apr 20223:14 pmRNSNet Asset Value(s)
1st Apr 202210:43 amRNSTotal Voting Rights
10th Mar 20227:00 amRNSTransaction in Own Shares
4th Mar 20221:40 pmRNSDirector/PDMR Shareholding
4th Mar 202212:44 pmRNSTotal Voting Rights
4th Mar 202212:39 pmRNSIssue of Equity
2nd Mar 20222:26 pmRNSNet Asset Value(s)
1st Mar 20229:58 amRNSTotal Voting Rights
18th Feb 20221:27 pmRNSInterim Management Statement
15th Feb 20224:51 pmRNSTransaction in Own Shares
10th Feb 20227:00 amRNSIssue of Equity
9th Feb 202212:11 pmRNSOffer for Subscription - Update
7th Feb 202210:12 amRNSNet Asset Value(s)
3rd Feb 20221:34 pmRNSResult of AGM
1st Feb 202211:52 amRNSTotal Voting Rights
24th Jan 202210:17 amRNSOffer for Subscription and Issue of Prospectus
17th Jan 202212:44 pmRNSTransaction in Own Shares
6th Jan 20222:49 pmRNSNet Asset Value(s)
4th Jan 20229:41 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.